- Home
- OPK vs COLL Comparison
OPK vs COLL Comparison
Compare OPK & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPK
- COLL
- Stock Information
- Founded
- OPK 2007
- COLL 2002
- Country
- OPK United States
- COLL United States
- Employees
- OPK N/A
- COLL N/A
- Industry
- OPK Biotechnology: Pharmaceutical Preparations
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- OPK Health Care
- COLL Health Care
- Exchange
- OPK Nasdaq
- COLL Nasdaq
- Market Cap
- OPK N/A
- COLL 958.8M
- IPO Year
- OPK 1995
- COLL 2015
- Fundamental
- Price
- OPK $1.35
- COLL $31.97
- Analyst Decision
- OPK Buy
- COLL Strong Buy
- Analyst Count
- OPK 4
- COLL 4
- Target Price
- OPK $2.75
- COLL $43.75
- AVG Volume (30 Days)
- OPK 3.4M
- COLL 296.7K
- Earning Date
- OPK 08-06-2025
- COLL 08-07-2025
- Dividend Yield
- OPK N/A
- COLL N/A
- EPS Growth
- OPK N/A
- COLL N/A
- EPS
- OPK N/A
- COLL 1.25
- Revenue
- OPK $689,408,000.00
- COLL $664,283,000.00
- Revenue This Year
- OPK N/A
- COLL $20.04
- Revenue Next Year
- OPK $7.80
- COLL $3.98
- P/E Ratio
- OPK N/A
- COLL $25.18
- Revenue Growth
- OPK N/A
- COLL 17.17
- 52 Week Low
- OPK $1.21
- COLL $23.23
- 52 Week High
- OPK $2.04
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- OPK 53.25
- COLL 71.18
- Support Level
- OPK $1.33
- COLL $30.60
- Resistance Level
- OPK $1.38
- COLL $31.99
- Average True Range (ATR)
- OPK 0.04
- COLL 0.80
- MACD
- OPK 0.01
- COLL 0.17
- Stochastic Oscillator
- OPK 77.21
- COLL 95.50
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.